Glucocorticoids are the mainstay of treatment for patients with polymyalgia rheumatica (PMR) and often produce substantial clinical improvements, but treatment can be complicated by relapse, adverse ...

For patients with polymyalgia rheumatica with relapse during tapering of glucocorticoid therapy, treatment with sarilumab, the human monoclonal antibody that binds to the interleukin-6 receptor α, is ...

In patients with polymyalgia rheumatica with relapse during glucocorticoid tapering, interleukin-6 receptor antagonist sarilumab increased disease remission and reduced glucocorticoid exposure at 1 ...

In this article, the European League Against Rheumatism (EULAR) and American College of Rheumatology (ACR) present recommendations for the management of polymyalgia rheumatica (PMR). These ...

Please provide your email address to receive an email when new articles are posted on . Patients were more likely to achieve sustained remission with sarilumab vs. placebo. The most common adverse ...

In this article, Lally and colleagues present the results of an open-label trial of the anti-interleukin (IL)-6 receptor agent tocilizumab in 10 patients with isolated polymyalgia rheumatica (PMR).

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. So this is certainly an exciting time to ...

Failed trial in giant cell arteritis also published the same day ...

Polymyalgia rheumatica (PMR) is an inflammatory disorder that causes severe muscle pain, muscle stiffness, muscle spasms and cramping on both sides of the body, particularly in the shoulders, neck, ...